Portfolio Companies News
October 9, 2019Nordic Nanovector Presentations at ...
Oslo, Norway, 9 October 2019 Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators at Orano Med will present data and analyses from preclinical studies with 212Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the treatment of leukaemia and lymphoma at t... read more
October 9, 2019GenSight Biologics reports evidence...
First study to find direct evidence that therapeutic gene is transferred from the injected eye to the uninjected contralateral eye of primates Findings support mechanism for bilateral visual improvement with unilateral GS010 gene therapy, which was consistently observed in LHON subjects in th... read more
October 9, 2019Targovax selected for oral presenta...
Oslo, Norway, 9 October 2019 – Targovax ASA (OSE: TRVX), announces that clinical data on the company’s lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented at the Socie... read more
October 8, 2019Camel-IDS appoints Ruggero Della Bi...
Brussels (Belgium), 8 October 2019 Camel-IDS, a privately-held biotechnology company developing novel radiopharmaceuticals, today announced the appointment of Ruggero Della Bitta MD, PhD, as Chief Medical Officer of Camel-IDS, effective October 1, 2019. Dr. Della Bitta has more than 25 years o... read more
October 8, 2019GenSight Biologics Appoints Magali ...
Paris, France, October 8, 2019, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, ann... read more
August 01, 2019Q2 2019 General Market Overview
Since the start in 1996, HealthCap funds have invested in 114 portfolio companies.
43 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.